CLINICAL TRIALS PROFILE FOR LURBINECTEDIN
✉ Email this page to a colleague
All Clinical Trials for lurbinectedin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01314599 ↗ | Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | Completed | PharmaMar | Phase 1 | 2011-05-01 | Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183. |
NCT01831089 ↗ | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | PharmaMar | Phase 1 | 2013-09-01 | Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors |
NCT01951157 ↗ | A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | Completed | PharmaMar | Phase 2 | 2013-09-11 | A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for lurbinectedin
Condition Name
Clinical Trial Locations for lurbinectedin
Trials by Country
Clinical Trial Progress for lurbinectedin
Clinical Trial Phase
Clinical Trial Sponsors for lurbinectedin
Sponsor Name